Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors

Michelle Goulette,Nicolas J. Schlienz,Amy A. Case,Eric Hansen,Cheryl Rivard,Rebecca L. Ashare,Maciej L. Goniewicz,Maansi Bansal-Travers,Andrew Hyland,Danielle M. Smith
DOI: https://doi.org/10.1007/s00520-024-08374-w
IF: 3.1
2024-03-06
Supportive Care in Cancer
Abstract:Cannabis use may introduce risks and/or benefits among people living with cancer, depending on product type, composition, and nature of its use. Patient knowledge of tetrahydrocannabinol (THC) or cannabidiol (CBD) concentration could provide information for providers about cannabis use during and after treatment that may aide in risk and benefit assessments. This study aimed to examine knowledge of THC or CBD concentration among patients living with cancer who consume cannabis, and factors associated with knowledge of cannabinoid concentrations.
oncology,health care sciences & services,rehabilitation
What problem does this paper attempt to address?